Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

A Duchenne mus­cu­lar dy­s­tro­phy pa­tient died of car­diac ar­rest on Fri­day in a Phase 2 tri­al of Pfiz­er’s gene ther­a­py, the phar­ma com­pa­ny con­firmed.

The pa­tient re­ceived for­dadis­tro­gene mova­parvovec in ear­ly 2023 as part of Pfiz­er’s DAY­LIGHT study en­rolling pa­tients 2 and 3 years old. As a re­sult of the boy’s death, Pfiz­er is paus­ing dos­ing in the crossover por­tion of its Phase 3 CIFFREO study in pa­tients 4 to 7 years old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.